The Acrovan Corporation is a full service CRO, founded in 2002. It provides the following core services.

• IND filing and government affairs for the Korean FDA
• Data management and statistics
• PI selection and site evaluation
• Monitoring

Since its establishment, Acrovan has been expanding its business field and territory with a highly customer oriented policy and constructive IT strategy. It has accumulated abundant experience in domestic and global clinical studies, including those of foreign sponsors.
Currently, Korea is one of the most important and attractive countries in Asia for carrying out clinical studies. Domestic increase in the number of multinational trials performed in Korea ( from 5 studies in 2000 to more than 100 studies in 2006), eloquently shows the advantage of performing clinical studies here and Korea's competitiveness in clinical development is strongly supported by the following environmental factors.

• The Korean regulatory process is effectively streamlined compared with some other Asian countries.
• Many investigators are well trained and experienced in ICH-GCP.
• There is an advanced medical infrastructure.
• Patients have the same genetic polymorphism and disease profiles compared with other Asian populations.

Acrovan provides a positive outsourcing experience through the carefully managed application of industry expertise and effective management of client relationships.

For further information, see www.acrovan.com